COMPANY PRODUCT TYPE THERAPEUTIC AREA INDICATION PHASE PRODUCT
AbbVie ABBV-181 Biodrugs/ Drugs Cancer Solid tumors / Head cancer / Neck cancer 1PhI ABBV-181
Therapeutic area: Cancer
AbbVie Humira (adalimumab) Biodrugs/ Drugs Autoimmune & Inflammation Hidradenitis Suppurativa / Uveitis / Ulcerative colitis/ Chron Disease / Rheumatoid Arthritis / Psoriasis / Psoriatic Arthritis 4Reg. Humira (adalimumab)
Therapeutic area: Autoimmune & Inflammation
AbbVie ABBV-621 Biodrugs/ Drugs Cancer Colorrectal cancer / Acute Myeloid Leukemia 1PhI ABBV-621
Therapeutic area: Cancer
AbbVie ABT-SLV187 Biodrugs/ Drugs Central Nervous System Parkinson 4Reg. ABT-SLV187
Therapeutic area: Central Nervous System
AbbVie ABBV-8E12 Biodrugs/ Drugs Central Nervous System Alzheimer 2PhII ABBV-8E12
Therapeutic area: Central Nervous System
AbbVie ABT-199/GDC0199 Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Chronic Lymphocytic Leukemia / Mieloma Multiple / Leucemia Mieloide Aguda 3PhIII ABT-199/GDC0199
Therapeutic area: Blood and Lymphatic systems / Cancer
AbbVie ABBV-927 Biodrugs/ Drugs Cancer Solid tumors 1PhI ABBV-927
Therapeutic area: Cancer
AbbVie ABT-494 Biodrugs/ Drugs Autoimmune & Inflammation Rheumatoid arthritis / Chron Disease / Ulcerative Colitis/ Atopic Dermatitis / Psoriasic Arthritis / Axial Spondiloarthritis / Giant Cell Artheritis / Juvenil Idiopatic Arthritis / Lupus / Ankylosing Spondylitis 3PhIII ABT-494
Therapeutic area: Autoimmune & Inflammation
AbbVie ABT-066 Biodrugs/ Drugs Autoimmune & Inflammation Psoriasis / Psoriatic arthritis / Crohn disease / Ulcerative colitis / Hidrosadenitis Supurativa 3PhIII ABT-066
Therapeutic area: Autoimmune & Inflammation
AbbVie Veliparib Biodrugs/ Drugs Cancer Breast Cancer / Ovarian cancer 3PhIII Veliparib
Therapeutic area: Cancer
AbbVie ABBV-399 Biodrugs/ Drugs Cancer NSCLC 2PhII ABBV-399
Therapeutic area: Cancer
AbbVie ABBV-323 Biodrugs/ Drugs Autoimmune & Inflammation Ulcerative colitis 2PhII ABBV-323
Therapeutic area: Autoimmune & Inflammation
Amgen Romiplostim Biodrugs/ Drugs Blood and Lymphatic systems Adult chronic - immune (idiopatic)-thrombocytopenic-purpura (ITP) 4Reg. Romiplostim
Therapeutic area: Blood and Lymphatic systems
Amgen Evolocumab Biodrugs/ Drugs Cardiovascular and circulatory systems
Metabolic / Endocrinology
Hypercholesterolemia, mixed dyslipidemia and Homozygous familial hypercholesterolemia 4Reg. Evolocumab
Therapeutic area: Cardiovascular and circulatory systems / Metabolic / Endocrinology
Amgen Denosumab Biodrugs/ Drugs Musculoskeletal Disorders Osteoporosis in postmenopausal women / Treatment of bone loss associated with hormone ablation in men with prostate cancer 4Reg. Denosumab
Therapeutic area: Musculoskeletal Disorders
Amgen Talimogene laherparepvec Biodrugs/ Drugs Cancer Malignant melanoma 4Reg. Talimogene laherparepvec
Therapeutic area: Cancer
Amgen Blinatumomab Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Acute lymphoblastic leukaemia 4Reg. Blinatumomab
Therapeutic area: Blood and Lymphatic systems / Cancer
Amgen Cinacalcet Biodrugs/ Drugs Autoimmune & Inflammation
Kidney and Genitourinary system
Secondary hyperparathyroidism / Reducation of hypercalcaemia in patinents with parathyroid carcinoma or primary HPT 4Reg. Cinacalcet
Therapeutic area: Autoimmune & Inflammation / Kidney and Genitourinary system
Amgen Denosumab Biodrugs/ Drugs Cancer Giant cell tumour of the bone 2PhII Denosumab
Therapeutic area: Cancer
Amgen Etelcalcetide Biodrugs/ Drugs Metabolic / Endocrinology Secondary Hyperparathyroidism 4Reg. Etelcalcetide
Therapeutic area: Metabolic / Endocrinology
Amgen Omecantiv mecarbil Biodrugs/ Drugs Cardiovascular and circulatory systems Heart failure 3PhIII Omecantiv mecarbil
Therapeutic area: Cardiovascular and circulatory systems
Amgen Romosozumab Biodrugs/ Drugs Musculoskeletal Disorders
Women´s health
Postmenopausal osteoporosis 3PhIII Romosozumab
Therapeutic area: Musculoskeletal Disorders / Women´s health
Celgene CC 486 Biodrugs/ Drugs Blood and Lymphatic systems Lymphoma 1PhI CC 486
Therapeutic area: Blood and Lymphatic systems
Celgene Morgensen (GED-0301) Biodrugs/ Drugs Autoimmune & Inflammation
Digestive System
Ulcerative colitis 2PhII Morgensen (GED-0301)
Therapeutic area: Autoimmune & Inflammation / Digestive System
Celgene PD-L1 Inhibitor: durvalumab Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Myelodysplastic Syndromes (MDS) Acute Myeloid Leukemia (AML) 2PhII PD-L1 Inhibitor: durvalumab
Therapeutic area: Blood and Lymphatic systems / Cancer
Celgene REVLIMID® (lenalidomide) Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Diffuse large B-cell lymphoma (ABC subtype): First line Indolent lymphoma: relapsed/refractory Follicular lymphoma: first line 3PhIII REVLIMID® (lenalidomide)
Therapeutic area: Blood and Lymphatic systems / Cancer
Celgene CD19 CAR-T (JCAR017) Biodrugs/ Drugs Blood and Lymphatic systems Aggressive large B-cell lymphoma: Relapsed/refractory 1PhI CD19 CAR-T (JCAR017)
Therapeutic area: Blood and Lymphatic systems
Celgene CC-486 Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Myelodysplastic Syndromes (MDS): lower-risk Post-induction AML maintenance 3PhIII CC-486
Therapeutic area: Blood and Lymphatic systems / Cancer
Celgene CC 486 Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Breast: Metastatic Non-small cell lung: Advanced Myelodysplastic Syndromes (MDS): post hypomethylating agent (HMA) failure 2PhII CC 486
Therapeutic area: Blood and Lymphatic systems / Cancer
Celgene VIDAZA® (azacitidine for injection) Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Acute myeloid laeukemia (AML) (>30% blasts) 4Reg. VIDAZA® (azacitidine for injection)
Therapeutic area: Blood and Lymphatic systems / Cancer
Gilead Sciences GS-4997 (ASK-1 inhibitor) Biodrugs/ Drugs Digestive System Nonalcoholic steatohaepatitis 2PhII GS-4997 (ASK-1 inhibitor)
Therapeutic area: Digestive System
Gilead Sciences GS-5806 (fusion inhibitor) Biodrugs/ Drugs Infections
Respiratory and Pulmonary system
Respiratory syncytial virus 2PhII GS-5806 (fusion inhibitor)
Therapeutic area: Infections / Respiratory and Pulmonary system
Gilead Sciences Simtuzumab Biodrugs/ Drugs Digestive System Liver fibrosis, primary sclerosing cholangitis, nonalcoholic steatohaepatitis 2PhII Simtuzumab
Therapeutic area: Digestive System
Gilead Sciences GS-6615 (late sodium current inhibitor) Biodrugs/ Drugs Cardiovascular and circulatory systems Ventricular tachycardia / Ventricular fibrillation 2PhII GS-6615 (late sodium current inhibitor)
Therapeutic area: Cardiovascular and circulatory systems
Gilead Sciences Simtuzumab Biodrugs/ Drugs Respiratory and Pulmonary system Idiopathic pulmonary fibrosis 2PhII Simtuzumab
Therapeutic area: Respiratory and Pulmonary system
Gilead Sciences GS-4997 (ASK-1 inhibitor) Biodrugs/ Drugs Cardiovascular and circulatory systems Pulmonary arterial hypertension 2PhII GS-4997 (ASK-1 inhibitor)
Therapeutic area: Cardiovascular and circulatory systems
Gilead Sciences GS-5745 (MMP9 mAb inhibitor) Biodrugs/ Drugs Autoimmune & Inflammation Ulcerative colitis 2PhII GS-5745 (MMP9 mAb inhibitor)
Therapeutic area: Autoimmune & Inflammation
Gilead Sciences GS-5745 (MMP9 mAb inhibitor) Biodrugs/ Drugs Cancer Solid tumors 2PhII GS-5745 (MMP9 mAb inhibitor)
Therapeutic area: Cancer
Gilead Sciences Momelotinib Biodrugs/ Drugs Cancer Pancreatic cancer 2PhII Momelotinib
Therapeutic area: Cancer
Gilead Sciences Emtricitabine/Tenofovir alafenamide FDC/ Bictegravir/ Emtricitabine/Tenofovir Biodrugs/ Drugs Infections HIV/AIDS - PreExposure Profilaxis 3PhIII Emtricitabine/Tenofovir alafenamide FDC/ Bictegravir/ Emtricitabine/Tenofovir
Therapeutic area: Infections
Gilead Sciences Alafenamide STR Biodrugs/ Drugs Infections HIV/AIDS 3PhIII Alafenamide STR
Therapeutic area: Infections
Gilead Sciences Emtricitabine/Tenofovir alafenamide FDC Biodrugs/ Drugs Infections HIV/AIDS 3PhIII Emtricitabine/Tenofovir alafenamide FDC
Therapeutic area: Infections
Gilead Sciences Elvitegravir/Cobicistat /Emtricitabine/Tenofovir alafenamide STR Biodrugs/ Drugs Infections HIV/AIDS 3PhIII Elvitegravir/Cobicistat /Emtricitabine/Tenofovir alafenamide STR
Therapeutic area: Infections
Incyte Biosciences Iberia INCMGA0012 Biodrugs/ Drugs Cancer Anal cancer (In collaboration with MacroGenics) 2PhII INCMGA0012
Therapeutic area: Cancer
Incyte Biosciences Iberia Itacitinib Biodrugs/ Drugs Cancer Chronic graft-versus-host disease 3PhIII Itacitinib
Therapeutic area: Cancer
Incyte Biosciences Iberia INCB01158 Biodrugs/ Drugs Cancer Solid tumors (Co-development with Calithera) 2PhII INCB01158
Therapeutic area: Cancer
Incyte Biosciences Iberia Itacitinib Biodrugs/ Drugs Cancer Non-small cell lung cancer (with osimertinib) (In collaboration with AstraZeneca) 2PhII Itacitinib
Therapeutic area: Cancer
Incyte Biosciences Iberia INCAGN1876 Biodrugs/ Drugs Cancer Solid tumors (Discovery alliance with Agenus) 2PhII INCAGN1876
Therapeutic area: Cancer
Incyte Biosciences Iberia Pemigatinib Biodrugs/ Drugs Cancer Bladder cancer 2PhII Pemigatinib
Therapeutic area: Cancer
Incyte Biosciences Iberia Pemigatinib Biodrugs/ Drugs Cancer Cholangiocarcinoma 2PhII Pemigatinib
Therapeutic area: Cancer
Incyte Biosciences Iberia Pemigatinib Biodrugs/ Drugs Cancer 8p11 MPN 2PhII Pemigatinib
Therapeutic area: Cancer
Incyte Biosciences Iberia Parsaclisib Biodrugs/ Drugs Cancer Follicular lymphoma 2PhII Parsaclisib
Therapeutic area: Cancer
Incyte Biosciences Iberia Parsaclisib Biodrugs/ Drugs Cancer Marginal zone lymphoma 2PhII Parsaclisib
Therapeutic area: Cancer
Incyte Biosciences Iberia Parsaclisib Biodrugs/ Drugs Cancer Mantle cell lymphoma 2PhII Parsaclisib
Therapeutic area: Cancer
Incyte Biosciences Iberia INCMGA0012 Biodrugs/ Drugs Cancer MSI-H endometrial cancer (In collaboration with MacroGenics) 1PhI INCMGA0012
Therapeutic area: Cancer
Incyte Biosciences Iberia INCMGA0012 Biodrugs/ Drugs Cancer Merkel cell carcinoma (In collaboration with MacroGenics) 2PhII INCMGA0012
Therapeutic area: Cancer
Merck KGaA Avelumab Biodrugs/ Drugs Cancer anti-PD-L1 mAb. Several types of cancer (Merkel cell cancer 1L / urothelial cancer / solid tumors and non-small cell lung cancer 1L in combination with talazoparib, axitinib, ALK inhibitors, cetuximab, or chemotherapy). 2PhII Avelumab
Therapeutic area: Cancer
Merck KGaA Abituzumab Biodrugs/ Drugs Cancer pan-αν integrin inhibiting mAb. Colorectal Cancer 1L 2PhII Abituzumab
Therapeutic area: Cancer
Merck KGaA Atacicept Biodrugs/ Drugs Autoimmune & Inflammation Anti-BlyS/APRIL fusion protein. Systemic lupus erythematosus / IgA nephropathy 2PhII Atacicept
Therapeutic area: Autoimmune & Inflammation
Novo Nordisk Pharma Semaglutide Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 2 3PhIII Semaglutide
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Liraglutide Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 2 in paediatric population 3PhIII Liraglutide
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Nonacog beta pegol Biodrugs/ Drugs Blood and Lymphatic systems Haemophilia B 4Reg. Nonacog beta pegol
Therapeutic area: Blood and Lymphatic systems
Novo Nordisk Pharma IDegAsp (combination insulin degludec + insulin aspart) Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 2 and type 1 4Reg. IDegAsp (combination insulin degludec + insulin aspart)
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma N8-GP (glycopegylated recombinant FVIII) Biodrugs/ Drugs Blood and Lymphatic systems Haemophilia A 3PhIII N8-GP (glycopegylated recombinant FVIII)
Therapeutic area: Blood and Lymphatic systems
Novo Nordisk Pharma Somapacitan(Long-acting growth hormone) Biodrugs/ Drugs Metabolic / Endocrinology Growth hormone deficiency 3PhIII Somapacitan(Long-acting growth hormone)
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma IDegLira (combination insulin degludec + liraglutide) Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 2 4Reg. IDegLira (combination insulin degludec + liraglutide)
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Concizumab Biodrugs/ Drugs Blood and Lymphatic systems Haemophilia A and B 2PhII Concizumab
Therapeutic area: Blood and Lymphatic systems
Novo Nordisk Pharma Faster-acting insulin aspart (FIAsp) Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 1 and type 2 4Reg. Faster-acting insulin aspart (FIAsp)
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Liraglutide 3mg Biodrugs/ Drugs Metabolic / Endocrinology Obesity 4Reg. Liraglutide 3mg
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Monoclonal antibody anti Il-21 Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 1 2PhII Monoclonal antibody anti Il-21
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Turoctocog alfa Biodrugs/ Drugs Blood and Lymphatic systems Haemophilia A 4Reg. Turoctocog alfa
Therapeutic area: Blood and Lymphatic systems
Novo Nordisk Pharma Oral semaglutide Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 2 3PhIII Oral semaglutide
Therapeutic area: Metabolic / Endocrinology
prueba prueba Biodrugs/ Drugs Blood and Lymphatic systems sdad 2PhII prueba
Therapeutic area: Blood and Lymphatic systems
Roche IMGATUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 2PhII IMGATUZUMAB
Therapeutic area: Cancer
Roche PERJETA Biodrugs/ Drugs Cancer Malignant neoplasm of stomach 3PhIII PERJETA
Therapeutic area: Cancer
Roche TARCEVA Biodrugs/ Drugs Cancer Malignant neoplasm of other and ill-defined sites 2PhII TARCEVA
Therapeutic area: Cancer
Roche CIF MEK INH Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI CIF MEK INH
Therapeutic area: Cancer
Roche BITOPERTIN Biodrugs/ Drugs Central Nervous System Schizophrenia 3PhIII BITOPERTIN
Therapeutic area: Central Nervous System
Roche MERICITABINE Biodrugs/ Drugs Infections Chronic viral haepatitis 2PhII MERICITABINE
Therapeutic area: Infections
Roche APITOLISIB Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI APITOLISIB
Therapeutic area: Cancer
Roche AVASTIN Biodrugs/ Drugs Cancer Malignant neoplasm of brain 3PhIII AVASTIN
Therapeutic area: Cancer
Roche LUMRETUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of breast 1PhI LUMRETUZUMAB
Therapeutic area: Cancer
Roche MABTHERA Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Other + unspecif. types of non-Hodgkin's lymphoma 3PhIII MABTHERA
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche DANOPREVIR Biodrugs/ Drugs Infections Chronic viral haepatitis 2PhII DANOPREVIR
Therapeutic area: Infections
Roche KADCYLA Biodrugs/ Drugs Cancer Malignant neoplasm of breast 3PhIII KADCYLA
Therapeutic area: Cancer
Roche AVASTIN Biodrugs/ Drugs Cancer Malignant neoplasm of cervix uteri 2PhII AVASTIN
Therapeutic area: Cancer
Roche IMGATUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of colon/rectum 2PhII IMGATUZUMAB
Therapeutic area: Cancer
Roche TASELISIB Biodrugs/ Drugs Cancer Malignant neoplasm of breast 3PhIII TASELISIB
Therapeutic area: Cancer
Roche TARCEVA Biodrugs/ Drugs Cancer Malignant neoplasm of pancreas 2PhII TARCEVA
Therapeutic area: Cancer
Roche EM MS BIOMARKER Biodrugs/ Drugs Autoimmune & Inflammation
Digestive System
Crohn's disease 1PhI EM MS BIOMARKER
Therapeutic area: Autoimmune & Inflammation / Digestive System
Roche OCRELIZUMAB Biodrugs/ Drugs Central Nervous System Musculoskeletal Disorders 3PhIII OCRELIZUMAB
Therapeutic area: Central Nervous System
Roche ONARTUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of brain 2PhII ONARTUZUMAB
Therapeutic area: Cancer
Roche BRAF KIN INH (2) Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 1PhI BRAF KIN INH (2)
Therapeutic area: Cancer
Roche AVASTIN Biodrugs/ Drugs Cancer Malignant neoplasm of ovary 3PhIII AVASTIN
Therapeutic area: Cancer
Roche ERIVEDGE Biodrugs/ Drugs Cancer Malignant neoplasm of other and ill-defined sites 2PhII ERIVEDGE
Therapeutic area: Cancer
Roche LUMRETUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 1PhI LUMRETUZUMAB
Therapeutic area: Cancer
Roche PEGASYS Biodrugs/ Drugs Infections Chronic viral haepatitis 3PhIII PEGASYS
Therapeutic area: Infections
Roche DULIGOTUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of colon/rectum 2PhII DULIGOTUZUMAB
Therapeutic area: Cancer
Roche KADCYLA Biodrugs/ Drugs Cancer Malignant neoplasm of stomach 3PhIII KADCYLA
Therapeutic area: Cancer
Roche LIFASTUZUMAB VEDOTIN Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 1PhI LIFASTUZUMAB VEDOTIN
Therapeutic area: Cancer
Roche IPATASERTIB Biodrugs/ Drugs Cancer Malignant neoplasm of breast 2PhII IPATASERTIB
Therapeutic area: Cancer
Roche VENETOCLAX Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Lymphoid leukaemia 3PhIII VENETOCLAX
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche XELODA Biodrugs/ Drugs Cancer Malignant neoplasm of other and ill-defined sites 2PhII XELODA
Therapeutic area: Cancer
Roche ALEGLITAZAR Biodrugs/ Drugs Cardiovascular and circulatory systems
Metabolic / Endocrinology
Atherosclerosis 3PhIII ALEGLITAZAR
Therapeutic area: Cardiovascular and circulatory systems / Metabolic / Endocrinology
Roche ONARTUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of breast 2PhII ONARTUZUMAB
Therapeutic area: Cancer
Roche CEA IL2V Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI CEA IL2V
Therapeutic area: Cancer
Roche AVASTIN Biodrugs/ Drugs Cancer Malignant neoplasm of stomach 3PhIII AVASTIN
Therapeutic area: Cancer
Roche DULIGOTUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasms 2PhII DULIGOTUZUMAB
Therapeutic area: Cancer
Roche OCRELIZUMAB Biodrugs/ Drugs Autoimmune & Inflammation
Musculoskeletal Disorders
Rheumatoid arthritis 3PhIII OCRELIZUMAB
Therapeutic area: Autoimmune & Inflammation / Musculoskeletal Disorders
Roche ERIVEDGE Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 2PhII ERIVEDGE
Therapeutic area: Cancer
Roche LUMRETUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 1PhI LUMRETUZUMAB
Therapeutic area: Cancer
Roche TAMIFLU Biodrugs/ Drugs Infections Influenza 1PhI TAMIFLU
Therapeutic area: Infections
Roche OX40 Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI OX40
Therapeutic area: Cancer
Roche IPATASERTIB Biodrugs/ Drugs Cancer Malignant neoplasm of prostate 2PhII IPATASERTIB
Therapeutic area: Cancer
Roche XOLAIR Biodrugs/ Drugs Autoimmune & Inflammation
Dermatology
Dermatitis (Allergic Contact) 3PhIII XOLAIR
Therapeutic area: Autoimmune & Inflammation / Dermatology
Roche ZELBORAF Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 2PhII ZELBORAF
Therapeutic area: Cancer
Roche ALEGLITAZAR Biodrugs/ Drugs Metabolic / Endocrinology Diabetes Mellitus 3PhIII ALEGLITAZAR
Therapeutic area: Metabolic / Endocrinology
Roche PARSATUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of colon/rectum 2PhII PARSATUZUMAB
Therapeutic area: Cancer
Roche COBIMETINIB Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 1PhI COBIMETINIB
Therapeutic area: Cancer
Roche DALCETRAPIB Biodrugs/ Drugs Cardiovascular and circulatory systems Acute myocardial infarction 3PhIII DALCETRAPIB
Therapeutic area: Cardiovascular and circulatory systems
Roche EM ACTEMAB RA Biodrugs/ Drugs Autoimmune & Inflammation
Musculoskeletal Disorders
Rheumatoid arthritis 2PhII EM ACTEMAB RA
Therapeutic area: Autoimmune & Inflammation / Musculoskeletal Disorders
Roche OCRELIZUMAB Biodrugs/ Drugs Autoimmune & Inflammation
Musculoskeletal Disorders
Systemic lupus erythematosus 3PhIII OCRELIZUMAB
Therapeutic area: Autoimmune & Inflammation / Musculoskeletal Disorders
Roche ERIVEDGE Biodrugs/ Drugs Autoimmune & Inflammation
Cancer
Other disorders involving the immune mechanism 2PhII ERIVEDGE
Therapeutic area: Autoimmune & Inflammation / Cancer
Roche PDL1 MAB Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 1PhI PDL1 MAB
Therapeutic area: Cancer
Roche TASPOGLUTIDE Biodrugs/ Drugs Metabolic / Endocrinology Diabetes Mellitus 3PhIII TASPOGLUTIDE
Therapeutic area: Metabolic / Endocrinology
Roche PLGF MAB Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 1PhI PLGF MAB
Therapeutic area: Cancer
Roche IPATASERTIB Biodrugs/ Drugs Cancer Malignant neoplasm of stomach 2PhII IPATASERTIB
Therapeutic area: Cancer
Roche ACTEMRA Biodrugs/ Drugs Autoimmune & Inflammation Other disorders involving the immune mechanism 3PhIII ACTEMRA
Therapeutic area: Autoimmune & Inflammation
Roche COBIMETINIB Biodrugs/ Drugs Cancer Malignant melanoma of skin 3PhIII COBIMETINIB
Therapeutic area: Cancer
Roche PDL1 MAB Biodrugs/ Drugs Cancer Malignant neoplasm of kidney except renal pelvis 2PhII PDL1 MAB
Therapeutic area: Cancer
Roche COBIMETINIB Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI COBIMETINIB
Therapeutic area: Cancer
Roche DALCETRAPIB Biodrugs/ Drugs Cardiovascular and circulatory systems
Metabolic / Endocrinology
Atherosclerosis 3PhIII DALCETRAPIB
Therapeutic area: Cardiovascular and circulatory systems / Metabolic / Endocrinology
Roche GAZYVA Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Lymphoid leukaemia 2PhII GAZYVA
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche PDL1 MAB Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 3PhIII PDL1 MAB
Therapeutic area: Cancer
Roche FORTOVASE Biodrugs/ Drugs Infections HIV disease unspecified 2PhII FORTOVASE
Therapeutic area: Infections
Roche PDL1 MAB Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI PDL1 MAB
Therapeutic area: Cancer
Roche VALCYTE Biodrugs/ Drugs Autoimmune & Inflammation Transplanted organ and tissue status (Excl. complications) 3PhIII VALCYTE
Therapeutic area: Autoimmune & Inflammation
Roche KADCYLA Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 2PhII KADCYLA
Therapeutic area: Cancer
Roche ACTEMRA Biodrugs/ Drugs Cardiovascular and circulatory systems Peripheral Vascular Diseases 3PhIII ACTEMRA
Therapeutic area: Cardiovascular and circulatory systems
Roche ETROLIZUMAB Biodrugs/ Drugs Autoimmune & Inflammation
Musculoskeletal Disorders
Irritable bowel syndrome 3PhIII ETROLIZUMAB
Therapeutic area: Autoimmune & Inflammation / Musculoskeletal Disorders
Roche PICTILISIB Biodrugs/ Drugs Cancer Malignant neoplasm of breast 2PhII PICTILISIB
Therapeutic area: Cancer
Roche DULIGOTUZUMAB Biodrugs/ Drugs Cancer Other malignant neoplasms of skin 1PhI DULIGOTUZUMAB
Therapeutic area: Cancer
Roche HCV POL INH PRO Biodrugs/ Drugs Infections Chronic viral haepatitis 3PhIII HCV POL INH PRO
Therapeutic area: Infections
Roche GAZYVA Biodrugs/ Drugs Cancer Malignant neoplasm of other and unspecified parts of biliary tract 3PhIII GAZYVA
Therapeutic area: Cancer
Roche ONARTUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 3PhIII ONARTUZUMAB
Therapeutic area: Cancer
Roche HERCEPTIN Biodrugs/ Drugs Cancer Malignant neoplasm of bladder 2PhII HERCEPTIN
Therapeutic area: Cancer
Roche TASELISIB Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 1PhI TASELISIB
Therapeutic area: Cancer
Roche XELODA Biodrugs/ Drugs Cancer Malignant neoplasm of colon/rectum 3PhIII XELODA
Therapeutic area: Cancer
Roche LEBRIKIZUMAB Biodrugs/ Drugs Respiratory and Pulmonary system Other diseases of upper respiratory tract 2PhII LEBRIKIZUMAB
Therapeutic area: Respiratory and Pulmonary system
Roche ACTEMRA Biodrugs/ Drugs Metabolic / Endocrinology Thyrotoxicosis (hyperthyroidism) 3PhIII ACTEMRA
Therapeutic area: Metabolic / Endocrinology
Roche APITOLISIB Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 1PhI APITOLISIB
Therapeutic area: Cancer
Roche ALECTINIB Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 3PhIII ALECTINIB
Therapeutic area: Cancer
Roche GANTENERUMAB Biodrugs/ Drugs Central Nervous System Alzheimer's disease 3PhIII GANTENERUMAB
Therapeutic area: Central Nervous System
Roche PICTILISIB Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 2PhII PICTILISIB
Therapeutic area: Cancer
Roche EM RA PRED DEV Biodrugs/ Drugs Autoimmune & Inflammation
Digestive System
Crohn's disease 1PhI EM RA PRED DEV
Therapeutic area: Autoimmune & Inflammation / Digestive System
Roche LAMPALIZUMAB Biodrugs/ Drugs Ophthalmology and optometry Retinal disorders other 4Reg. LAMPALIZUMAB
Therapeutic area: Ophthalmology and optometry
Roche GPC3 MAB Biodrugs/ Drugs Cancer Malignant neoplasm of liver 2PhII GPC3 MAB
Therapeutic area: Cancer
Roche ONARTUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of stomach 3PhIII ONARTUZUMAB
Therapeutic area: Cancer
Roche LIFASTUZUMAB VEDOTIN Biodrugs/ Drugs Cancer Malignant neoplasm of ovary 2PhII LIFASTUZUMAB VEDOTIN
Therapeutic area: Cancer
Roche VANUCIZUMAB Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI VANUCIZUMAB
Therapeutic area: Cancer
Roche ZELBORAF Biodrugs/ Drugs Cancer Malignant neoplasms 3PhIII ZELBORAF
Therapeutic area: Cancer
Roche APITOLISIB Biodrugs/ Drugs Cancer Malignant neoplasm of kidney except renal pelvis 2PhII APITOLISIB
Therapeutic area: Cancer
Roche GAZYVA Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Diffuse non-Hodgkin's lymphoma, unspecified 3PhIII GAZYVA
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche SEMBRAGILINE Biodrugs/ Drugs Central Nervous System Alzheimer's disease 2PhII SEMBRAGILINE
Therapeutic area: Central Nervous System
Roche ETROLIZUMAB Biodrugs/ Drugs Autoimmune & Inflammation
Digestive System
Crohn's disease 3PhIII ETROLIZUMAB
Therapeutic area: Autoimmune & Inflammation / Digestive System
Roche MABTHERA Biodrugs/ Drugs Cardiovascular and circulatory systems Other necrotizing vasculopathies 3PhIII MABTHERA
Therapeutic area: Cardiovascular and circulatory systems
Roche HPV16 TI Biodrugs/ Drugs Infections Viral agents as cause of diseases classified to other 2PhII HPV16 TI
Therapeutic area: Infections
Roche PDL1 MAB Biodrugs/ Drugs Cancer Malignant neoplasm of bladder 3PhIII PDL1 MAB
Therapeutic area: Cancer
Roche NEORECORMON Biodrugs/ Drugs Blood and Lymphatic systems Anaemia in neoplastic disease 2PhII NEORECORMON
Therapeutic area: Blood and Lymphatic systems
Roche VENETOCLAX Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Diffuse non-Hodgkin's lymphoma, unspecified 1PhI VENETOCLAX
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche MABTHERA Biodrugs/ Drugs Autoimmune & Inflammation
Dermatology
Pemphigus 3PhIII MABTHERA
Therapeutic area: Autoimmune & Inflammation / Dermatology
Roche BASIMGLURANT Biodrugs/ Drugs Genetic Diseases and Dysmorphic syndromes Fragile X Syndrome 2PhII BASIMGLURANT
Therapeutic area: Genetic Diseases and Dysmorphic syndromes
Roche GAZYVA Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Follicular (nodular) non-Hodgkin's lymphoma 3PhIII GAZYVA
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche VANUCIZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of colon/rectum 2PhII VANUCIZUMAB
Therapeutic area: Cancer
Roche IMGATUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of other and ill-defined sites 1PhI IMGATUZUMAB
Therapeutic area: Cancer
Roche IGF1R MAB Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 2PhII IGF1R MAB
Therapeutic area: Cancer
Roche PERJETA Biodrugs/ Drugs Cancer Malignant neoplasm of breast 3PhIII PERJETA
Therapeutic area: Cancer
Roche PATECLIZUMAB Biodrugs/ Drugs Autoimmune & Inflammation
Musculoskeletal Disorders
Rheumatoid arthritis 2PhII PATECLIZUMAB
Therapeutic area: Autoimmune & Inflammation / Musculoskeletal Disorders
Roche CD40 IMAB Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI CD40 IMAB
Therapeutic area: Cancer
Roche IMGATUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI IMGATUZUMAB
Therapeutic area: Cancer
Roche MABTHERA Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Diffuse non-Hodgkin's lymphoma, unspecified 3PhIII MABTHERA
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche CMV ANTI Biodrugs/ Drugs Infections Cytomegaloviral disease 2PhII CMV ANTI
Therapeutic area: Infections
Roche GAZYVA Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Lymphoid leukaemia 3PhIII GAZYVA
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche ALPHA7 NIC AGO Biodrugs/ Drugs Central Nervous System Alzheimer's disease 2PhII ALPHA7 NIC AGO
Therapeutic area: Central Nervous System
Roche IGF1R MAB Biodrugs/ Drugs Cancer Malignant neoplasms 2PhII IGF1R MAB
Therapeutic area: Cancer
Roche PERJETA Biodrugs/ Drugs Cancer Malignant neoplasm of ovary 3PhIII PERJETA
Therapeutic area: Cancer
Roche POLATUZUMAB VEDOTIN Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Follicular (nodular) non-Hodgkin's lymphoma 2PhII POLATUZUMAB VEDOTIN
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche CEA CD3 TCB Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI CEA CD3 TCB
Therapeutic area: Cancer
Roche IPATASERTIB Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI IPATASERTIB
Therapeutic area: Cancer
Roche MABTHERA Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Lymphoid leukaemia 3PhIII MABTHERA
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche CRENEZUMAB Biodrugs/ Drugs Central Nervous System Alzheimer's disease 3PhIII CRENEZUMAB
Therapeutic area: Central Nervous System
Roche GAZYVA Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Malignant neoplasms of lymphoid haematopoietic + 3PhIII GAZYVA
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche ANTI-INFLUENZA A Biodrugs/ Drugs Infections Influenza 2PhII ANTI-INFLUENZA A
Therapeutic area: Infections